Evotec (EVO) said Friday it opened its J.POD biologics development and manufacturing facility in Toulouse, France.
The facility, launched by the company's Just - Evotec Biologics unit, is expected to be operational in the second of 2024, and will enhance clinical and commercial biologics manufacturing capacity, the company said.
Evotec shares fell more than 6% in recent trading.
Price: 3.41, Change: -0.23, Percent Change: -6.32
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。